GT Biopharma commits $3.8M to University of Minnesota phase 1 trial of GTB-5550 in solid tumors

Filed April 7, 2026 · Period ending April 3, 2026 · ~1 min read

Key Changes

• high

  Company entered clinical trial agreement with University of Minnesota for phase 1a/1b study of GTB-5550, a tri-specific nanobody therapy, in advanced solid tumor patients who failed prior treatment

  Item 1.01 verify on EDGAR →
• high

  GT Biopharma will fund up to $3.8 million over three years for the study, representing a material cash commitment that will impact the company's burn rate and financial runway

  Item 1.01 verify on EDGAR →
• medium

  University of Minnesota will sponsor the IND application (IND 169118) and serve as sponsor investigator, shifting some regulatory responsibility to the academic institution

  Item 1.01 verify on EDGAR →